BACKGROUND: The role of adiponectin as a risk factor for mortality and recurrent ischemic cardiovascular events in patients with carotid artery disease is unknown. METHODS: Consecutive patients (n = 292) undergoing carotid endarterectomy for symptomatic and asymptomatic carotid stenosis were included in the study. Mortality and cardiovascular ischemic events were recorded during a median follow-up of 5.2 years. Baseline plasma concentrations of adiponectin were measured. Cox regression models stratified for gender were used for estimation of risk of events. RESULTS: Fifty-two patients died and 73 had an ischemic event (ischemic stroke, n = 52 and/or MI, n = 28) during follow-up. In univariate analyses, adiponectin was associated with mortality, hazard ratio (HR) per standard deviation (SD) increase of adiponectin, 1.46 (95% confidence interval [CI], 1.14-1.86). In multivariate analysis age, type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), plasma interleukin-6 (IL-6) and plasma adiponectin (HR per SD increase of adiponectin, 1.73 [95% CI, 1.29-2.32]) were independently associated with mortality. T2DM, CHD, fibrinogen, contralateral carotid artery stenosis, systolic blood pressure, symptomatic carotid artery stenosis were independently associated with ischemic events, whereas plasma adiponectin was not (HR per SD increase of adiponectin, 0.96 [95% CI, 0.75-1.23]). CONCLUSIONS: High plasma adiponectin concentration is associated with mortality in patients with established atherosclerosis undergoing surgery for carotid artery stenosis. Further studies to determine the role for adiponectin as a biomarker are warranted.
BACKGROUND: The role of adiponectin as a risk factor for mortality and recurrent ischemic cardiovascular events in patients with carotid artery disease is unknown. METHODS: Consecutive patients (n = 292) undergoing carotid endarterectomy for symptomatic and asymptomatic carotid stenosis were included in the study. Mortality and cardiovascular ischemic events were recorded during a median follow-up of 5.2 years. Baseline plasma concentrations of adiponectin were measured. Cox regression models stratified for gender were used for estimation of risk of events. RESULTS: Fifty-two patients died and 73 had an ischemic event (ischemic stroke, n = 52 and/or MI, n = 28) during follow-up. In univariate analyses, adiponectin was associated with mortality, hazard ratio (HR) per standard deviation (SD) increase of adiponectin, 1.46 (95% confidence interval [CI], 1.14-1.86). In multivariate analysis age, type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), plasma interleukin-6 (IL-6) and plasma adiponectin (HR per SD increase of adiponectin, 1.73 [95% CI, 1.29-2.32]) were independently associated with mortality. T2DM, CHD, fibrinogen, contralateral carotid artery stenosis, systolic blood pressure, symptomatic carotid artery stenosis were independently associated with ischemic events, whereas plasma adiponectin was not (HR per SD increase of adiponectin, 0.96 [95% CI, 0.75-1.23]). CONCLUSIONS: High plasma adiponectin concentration is associated with mortality in patients with established atherosclerosis undergoing surgery for carotid artery stenosis. Further studies to determine the role for adiponectin as a biomarker are warranted.
Authors: Gang Liu; Ming Ding; Stephanie E Chiuve; Eric B Rimm; Paul W Franks; James B Meigs; Frank B Hu; Qi Sun Journal: Arterioscler Thromb Vasc Biol Date: 2016-09-08 Impact factor: 8.311
Authors: Jonas Persson; Rona J Strawbridge; Olga McLeod; Karl Gertow; Angela Silveira; Damiano Baldassarre; Natalie Van Zuydam; Sonia Shah; Cristiano Fava; Stefan Gustafsson; Fabrizio Veglia; Bengt Sennblad; Malin Larsson; Maria Sabater-Lleal; Karin Leander; Bruna Gigante; Adam Tabak; Mika Kivimaki; Jussi Kauhanen; Rainer Rauramaa; Andries J Smit; Elmo Mannarino; Philippe Giral; Steve E Humphries; Elena Tremoli; Ulf de Faire; Lars Lind; Erik Ingelsson; Bo Hedblad; Olle Melander; Meena Kumari; Aroon Hingorani; Andrew D Morris; Colin N A Palmer; Pia Lundman; John Öhrvik; Stefan Söderberg; Anders Hamsten Journal: J Am Heart Assoc Date: 2015-08-14 Impact factor: 5.501
Authors: Claudia Menzaghi; Min Xu; Lucia Salvemini; Concetta De Bonis; Giuseppe Palladino; Tao Huang; Massimiliano Copetti; Yan Zheng; Yanping Li; Grazia Fini; Frank B Hu; Simonetta Bacci; Lu Qi; Vincenzo Trischitta Journal: Cardiovasc Diabetol Date: 2014-09-10 Impact factor: 9.951
Authors: Simona Hogas; Stefana C Bilha; Dumitru Branisteanu; Mihai Hogas; Abduzhappar Gaipov; Mehmet Kanbay; Adrian Covic Journal: Arch Med Sci Date: 2016-03-22 Impact factor: 3.318